Kiromic BioPharma Inc Ordinary Shares 주식 (OTC: KRBP)

에 대한 최신 뉴스 Kiromic BioPharma Inc Ordinary Shares (OTC:KRBP) 주식

Kiromic BioPharma

Major Institutional Interest

Biotech

News

Legal

General

KRBP

사기 혐의로 51개월 징역형 선고 및 610만 달러 배상 명령받은 남성 라스베이거스에 거주하는 55세의 미칼라이 콘틸라이(Mykalai Kontilai)는 목요일에 장기 사기 계획에 연루된 혐의로 징역 51개월과 배상금으로 610만 달러를 지불하라는 선고를 받았다. 이전에 마이클 콘틸레(Michael Contile)로 알려진 콘틸라이는 콜렉터스 카페(Collector&#39;s Café)라고도 알려진 그의 회사인 콜렉터스 커피(Collector&#39;s Coffee Inc.)를 통해 투자 사기를 주도했다.

주간 금융 범죄: 콘틸라이에 51개월 형 선고, 키로믹은 중요 정보 미공개로 기소

Kiromic BioPharma Inc Ordinary Shares

KIROMIC BIOPHARMA INC by Kiromic BioPharma, Inc.

Kiromic BioPharma Inc

WIIM

Morgan Stanley shares are trading higher after B of A Securities maintained its Buy rating on the stock, despite lowering the price target to $144.

B of A Securities analyst Craig Siegenthaler maintains Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) with a Buy and lowers the price target from $56 to $48.

Price Target

Analyst Ratings

VIRT

B of A Securities Maintains Buy on Virtu Finl, Lowers Price Target to $48

Hollywood loves a good power play, and&nbsp; the 55-year-old actress Ellen Pompeo just gave the industry one for the history books. The &#8220;Grey's Anatomy&#8221; star didn't just ask for a raise—she demanded a paycheck worthy of the highest-paid women in television. And she got it.
Before making headlines in 2017 with her $20 million per year contract, Pompeo had a conversation that set the wheels in motion. She reached out to Shonda Rhimes, the creator of &#8220;Grey's Anatomy,&#8221; for a little pre-negotiation blessing. While Rhimes had no say in salary decisions, she encouraged Pompeo to go for it.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100</a>.</li>
</ul>
<h2 class="wp-block-heading">A Negotiation That Changed the Game</h2>
&#8220;I said to her: ‘I'm going to go in and ask for this much. Are you cool with that?'" Pompeo recalled on the "<a href="https://www.youtube.com/watch?v=jex1tGfWpno&amp;ab_channel=CallHerDaddy">Call Her Daddy</a>" podcast. &#8220;[Rhimes] was like, ‘Yeah, no one's going to give it to you. You have to ask for it.'&#8221;
She asked for—and got—$575,000 per episode, making her the highest-paid actress in a primetime drama. The deal also included backend points and producing credits, pushing her earnings beyond just a base salary.
For Pompeo, this wasn't just about money—it was about power. &#8220;I became aware at a really early age that people with money had power,&#8221; she explained.
&nbsp;&#8220;I didn't have any power as a young woman. And I didn't like the way that felt. She added, "You don't have to be with any man you don't want to be with. For women, <a href="https://www.benzinga.com/personal-finance/25/01/43117114/it-wont-be-enough-financial-experts-warn-gen-x-about-key-retirement-pitfalls">financial </a>freedom is true independence."&nbsp;
Trending: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Pompeo was also well aware that &#8220;Grey's Anatomy&#8221; was a <a href="https://www.benzinga.com/news/25/02/44049133/last-week-jeff-bezos-lost-3-9-billion-in-a-day-woke-up-3-9-billion-richer-now-its-gone">billion-dollar franchise</a>. The show has generated nearly $3 billion for Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) since its debut, making it one of the company's most lucrative properties. Pompeo saw no reason why she shouldn't get her fair share.
&#8220;Women should always push the envelope. All anyone can say is no,&#8221; she added.
Pompeo's bold move reignited the conversation about gender pay disparity in Hollywood. The industry has long been criticized for underpaying female talent, even on blockbuster productions.
Disney, for example, recently agreed to a $43.3 million settlement in a lawsuit accusing the company of systematically paying women less than men for over a decade. While the company denied wrongdoing, the settlement spoke volumes about the persistent wage gap.
See Also: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Meanwhile, some argue that market forces—not discrimination—drive salary differences. In an interview with <a href="https://www.businessinsider.com/matthew-lillard-movie-and-tv-roles-shaggy-scream-2024-10">Business Insider</a>, Matthew Lillard revealed the impact of box office performance firsthand.&nbsp;
Following the underwhelming box office results of &#8220;Scooby-Doo 2: Monsters Unleashed,&#8221; Lillard feared for his career prospects, illustrating how financial outcomes can directly affect actors&#8217; opportunities and negotiations.
But others, like TV writer Katja Meier, see it differently. Meier, who has worked in television for over two decades, said ageism and sexism still dictate hiring and salary decisions. She founded Zenka Films to challenge industry biases and promote fair pay practices.
Pompeo's fight echoes past Hollywood salary showdowns. In 2005, the cast of &#8220;Desperate Housewives&#8221; united to demand equal pay, proving that strength lies in numbers. A decade later, Patricia Arquette used her Oscar speech to call out gender wage gaps, bringing mainstream attention to the issue.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

Ellen Pompeo Says Her $20 Million 'Grey's Anatomy' Deal Proves 'Financial Freedom Is True Independence'—And She's Urging Women To Ask For More

SPOT

Spotify Technology shares are trading higher after UBS maintained its Buy rating on the stock, despite lowering the price target to $690.

B of A Securities analyst Michael Carrier maintains Tradeweb Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TW#NASDAQ">TW</a>) with a Buy and raises the price target from $197 to $212.

B of A Securities Maintains Buy on Tradeweb Markets, Raises Price Target to $212

Needham analyst Mike Cikos reiterates Cognyte Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNT#NASDAQ">CGNT</a>) from Hold to Hold.

Reiteration

CGNT

Needham Reiterates Hold on Cognyte Softwareto Hold

Deep-pocketed investors have adopted a bearish approach towards Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AMAT usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Applied Mat. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 77% bearish. Among these notable options, 5 are puts, totaling $355,796, and 4 are calls, amounting to $506,989.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $135.0 to $220.0 for Applied Mat during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Applied Mat options trades today is 693.22 with a total volume of 990.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Applied Mat's big money trades within a strike price range of $135.0 to $220.0 over the last 30 days.
<h3>Applied Mat Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743614849_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$9.7</td>
<td>$9.6</td>
<td>$9.6</td>
<td>$145.00</td>
<td>$421.4K</td>
<td>304</td>
<td align="right">456</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$8.25</td>
<td>$8.15</td>
<td>$8.15</td>
<td>$145.00</td>
<td>$221.6K</td>
<td>525</td>
<td align="right">286</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$26.9</td>
<td>$26.0</td>
<td>$26.05</td>
<td>$170.00</td>
<td>$39.0K</td>
<td>1.5K</td>
<td align="right">16</td>
</tr>
<tr>
<td>AMAT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$57.15</td>
<td>$55.65</td>
<td>$57.15</td>
<td>$195.00</td>
<td>$34.2K</td>
<td>307</td>
<td align="right">6</td>
</tr>
<tr>
<td>AMAT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.6</td>
<td>$5.4</td>
<td>$5.52</td>
<td>$160.00</td>
<td>$33.1K</td>
<td>678</td>
<td align="right">98</td>
</tr>
</tbody>
</table>

<h3>About Applied Mat</h3>
Applied Materials Inc is the largest semiconductor wafer fabrication equipment, or WFE, manufacturer in the world. Applied Materials has a broad portfolio spanning nearly every corner of the WFE ecosystem. Specifically, Applied Materials holds a market share leadership position in deposition, which entails the layering of new materials on semiconductor wafers. It is more exposed to general-purpose logic chips made at integrated device manufacturers and foundries. It counts the largest chipmakers in the world as customers, including TSMC, Intel, and Samsung.
Following our analysis of the options activities associated with Applied Mat, we pivot to a closer look at the company's own performance.
<h3>Current Position of Applied Mat</h3>
<ul>
<li>With a volume of 2,208,774, the price of AMAT is up 2.4% at $149.16. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 43 days.</li>
</ul>
<h3>What Analysts Are Saying About Applied Mat</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $195.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Jefferies upgraded its action to Buy with a price target of $195. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Applied Mat with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

AMAT

Check Out What Whales Are Doing With AMAT

Deep-pocketed investors have adopted a bullish approach towards Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DAL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Delta Air Lines. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 33% bearish. Among these notable options, 5 are puts, totaling $559,507, and 13 are calls, amounting to $863,932.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $55.0 for Delta Air Lines over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Delta Air Lines's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Delta Air Lines's whale trades within a strike price range from $30.0 to $55.0 in the last 30 days. 
<h3>Delta Air Lines Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743614844_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$7.35</td>
<td>$7.15</td>
<td>$7.15</td>
<td>$40.00</td>
<td>$357.5K</td>
<td>1.5K</td>
<td>500</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.14</td>
<td>$2.1</td>
<td>$2.1</td>
<td>$50.00</td>
<td>$151.7K</td>
<td>1.6K</td>
<td>2.3K</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$4.6</td>
<td>$4.55</td>
<td>$4.6</td>
<td>$55.00</td>
<td>$117.3K</td>
<td>24</td>
<td>481</td>
</tr>
<tr>
<td>DAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$5.8</td>
<td>$5.7</td>
<td>$5.7</td>
<td>$47.00</td>
<td>$101.4K</td>
<td>235</td>
<td>208</td>
</tr>
<tr>
<td>DAL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.1</td>
<td>$2.08</td>
<td>$2.08</td>
<td>$50.00</td>
<td>$93.8K</td>
<td>1.6K</td>
<td>1.3K</td>
</tr>
</tbody>
</table>

<h3>About Delta Air Lines</h3>
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke network, where it gathers and distributes passengers across the globe through its biggest hubs in Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta has historically earned most of its international revenue and profits from flying passengers over the Atlantic Ocean.
<h3>Where Is Delta Air Lines Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,637,936, with DAL's price up by 1.7%, positioned at $43.14.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 7 days.</li>
</ul>
<h3>Expert Opinions on Delta Air Lines</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $70.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Delta Air Lines, maintaining a target price of $80. 
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Delta Air Lines, maintaining a target price of $60. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on Delta Air Lines, which currently sits at a price target of $72. 
&#x2A; An analyst from Raymond James persists with their Strong Buy rating on Delta Air Lines, maintaining a target price of $62. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Delta Air Lines, which currently sits at a price target of $77. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Delta Air Lines, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About Delta Air Lines

Whales with a lot of money to spend have taken a noticeably bearish stance on Adobe.
Looking at options history for Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 23% of the investors opened trades with bullish expectations and 38% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $283,549 and 7, calls, for a total amount of $258,625.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $285.0 and $470.0 for Adobe, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Adobe's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Adobe's whale activity within a strike price range from $285.0 to $470.0 in the last 30 days. 
<h3>Adobe Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743614838_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$93.45</td>
<td>$89.0</td>
<td>$89.0</td>
<td>$470.00</td>
<td>$89.0K</td>
<td>105</td>
<td align="right">10</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$4.2</td>
<td>$4.05</td>
<td>$4.07</td>
<td>$350.00</td>
<td>$81.4K</td>
<td>1.5K</td>
<td align="right">208</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$7.75</td>
<td>$7.4</td>
<td>$7.57</td>
<td>$400.00</td>
<td>$74.9K</td>
<td>858</td>
<td align="right">107</td>
</tr>
<tr>
<td>ADBE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$102.35</td>
<td>$101.2</td>
<td>$101.79</td>
<td>$285.00</td>
<td>$40.7K</td>
<td>0</td>
<td align="right">10</td>
</tr>
<tr>
<td>ADBE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$83.6</td>
<td>$82.4</td>
<td>$83.6</td>
<td>$465.00</td>
<td>$33.4K</td>
<td>357</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Adobe</h3>
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
<h3>Current Position of Adobe</h3>
<ul>
<li>Trading volume stands at 1,181,612, with ADBE's price up by 0.94%, positioned at $386.8.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 71 days.</li>
</ul>
<h3>What Analysts Are Saying About Adobe</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $462.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Baird persists with their Neutral rating on Adobe, maintaining a target price of $410. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Adobe, maintaining a target price of $430. 
&#x2A; An analyst from Keybanc persists with their Underweight rating on Adobe, maintaining a target price of $390. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on Adobe, which currently sits at a price target of $550. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $530.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Adobe with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

ADBE

Unpacking the Latest Options Trading Trends in Adobe

B of A Securities analyst Craig Siegenthaler maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Buy and raises the price target from $103 to $105.

NDAQ

B of A Securities Maintains Buy on Nasdaq, Raises Price Target to $105

Citigroup analyst Christopher Allen maintains Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) with a Neutral and lowers the price target from $125 to $105.

Citigroup Maintains Neutral on Stifel Financial, Lowers Price Target to $105

HC Wainwright &amp; Co. analyst Ed Arce reiterates Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) with a Buy and maintains $13 price target.

HC Wainwright & Co. Reiterates Buy on Inventiva, Maintains $13 Price Target

B of A Securities analyst Eli Abboud maintains MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) with a Underperform and raises the price target from $189 to $191.

MKTX

B of A Securities Maintains Underperform on MarketAxess Holdings, Raises Price Target to $191

FORT LAUDERDALE, FL / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 2, 2025 / Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced that it has entered into definitive agreements in a registered direct offering with institutional investors for the purchase and sale of approximately $2.46 million of shares of Common Stock and pre-funded warrants at a price of $2.07 per share of Common Stock. The entire transaction has been priced at the market under Nasdaq rules.
The offering consisted of the sale of 1,188,404 shares of Common Stock (or Pre-Funded Warrants). The offering price per Common Share is $2.07 (or $2.069 for each Pre-Funded Warrant, which is equal to the offering price per share of Common Stock to be sold in the offering minus an exercise price of $0.001 per Pre-Funded Warrant). The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full.

Offerings

SBFM

Sunshine Biopharma Announces $2.46M Registered Direct Offering At $2.07 A Share

Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>) is up 5% on Wednesday, with traders anticipating the <a href="https://www.benzinga.com/money/bonk-bonk-price-prediction">rally to continue further</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>)</td>
<td>$0.00001259</td>
<td>+4.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1759</td>
<td>+1.1%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001281</td>
<td>-1.3%</td>
</tr>
</tbody>
</table>
</figure>
What Happened: Crypto trader Cold Blooded Shiller pointed out that BONK has experienced a massive sweep of the lows, testing a historically significant level.
He emphasized that stability and confirmation are needed before confidence can build for a larger move.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BONK&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BONK</a> is another market I think is an interesting position with a huge attack on all of the lows. It needs to find some stability through this historic level to solidify. Relative simple TA, but still some work to be done here to increase confidence. <a href="https://t.co/AuqsitgrUC">pic.twitter.com/AuqsitgrUC</a>
&mdash; Cold Blooded Shiller (@ColdBloodShill) <a href="https://twitter.com/ColdBloodShill/status/1906833368861626854?ref_src=twsrc%5Etfw">March 31, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Analyst Crypto Chase <a href="https://x.com/Crypto_Chase/status/1907372326158578037">stated</a> that he is still holding 1% of his BONK position, watching how it interacts with the monthly support level that previously triggered a strong rally. 
This is its first retest in over a year, and he expects the meme coin to bounce towards more than $0.02 over time. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44604076/why-are-dogecoin-shiba-inu-down-over-15-in-the-past-week">Why Are Dogecoin, Shiba Inu Down Over 15% In The Past Week?</a>
Why It Matters: Bonk's price movement coincides with its recent <a href="https://x.com/bonk_inu/status/1905243483558015306?s=46">acquisition</a> of Exchange Art Marketplace, a major platform in the digital art sector. 
This strategic move could expand BONK's real-world utility, strengthen its presence within Solana's creator economy and drive long-term value growth as use cases increase.
Prominent trader Unipcs <a href="https://x.com/theunipcs/status/1907189126937395295">highlighted</a> Bonk's strength as one of the top-performing tokens in the top 100.
Another trader <a href="https://x.com/degengambleh/status/1907451385936855388">believes</a> it has the potential to join Dogecoin and Pepe in the $100 billion club at the market cycle's peak.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44403417/floki-dogecoin-shiba-inu-lead-in-meme-coin-holder-profitability-as-market-returns-to-valuation-from-6-months-ago">Floki, Dogecoin, Shiba Inu Lead In Meme Coin Holder Profitability As Market Returns To Valuation From 6 Months Ago</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BONK

$DOGE

$SHIB

Bonk Surges 5% In A Day, Outpacing Dogecoin, Shiba Inu: What's Driving The Rally?

Citigroup analyst Christopher Allen maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Neutral and lowers the price target from $60 to $50.

HOOD

Citigroup Maintains Neutral on Robinhood Markets, Lowers Price Target to $50

B of A Securities analyst Craig Siegenthaler maintains Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>) with a Buy and lowers the price target from $237 to $230.

B of A Securities Maintains Buy on Intercontinental Exchange, Lowers Price Target to $230

Citigroup analyst Christopher Allen maintains Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) with a Neutral and lowers the price target from $180 to $150.

Citigroup Maintains Neutral on Raymond James Finl, Lowers Price Target to $150

B of A Securities analyst Craig Siegenthaler maintains CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) with a Underperform and raises the price target from $200 to $219.

B of A Securities Maintains Underperform on CME Group, Raises Price Target to $219

Citigroup analyst Christopher Allen maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Buy and lowers the price target from $415 to $400.

LPLA

Citigroup Maintains Buy on LPL Finl Hldgs, Lowers Price Target to $400

Press Releases

Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial

Kiromic BioPharma's Deltacel Receives FDA Fast Track Designation

Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation

Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial

Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01

Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation

Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01

Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01

Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival

<h2 class="wp-block-heading">사기 혐의로 51개월 징역형 선고 및 610만 달러 배상 명령받은 남성</h2>
라스베이거스에 거주하는 55세의 미칼라이 콘틸라이(Mykalai Kontilai)는 목요일에 장기 사기 계획에 연루된 혐의로 징역 51개월과 배상금으로 610만 달러를 지불하라는 <a href="https://www.justice.gov/opa/pr/president-and-ceo-las-vegas-based-company-sentenced-role-investment-fraud-scheme-where-he" target="_blank" rel="noopener">선고</a>를 받았다. 이전에 마이클 콘틸레(Michael Contile)로 알려진 콘틸라이는 콜렉터스 카페(Collector&#8217;s Café)라고도 알려진 그의 회사인 콜렉터스 커피(Collector&#8217;s Coffee Inc.)를 통해 투자 사기를 주도했다.
미국 법무부에 따르면, 콘틸라이는 콜렉터스 커피의 CEO로서 2012년부터 2018년까지 회사가 스포츠 및 할리우드 기념품을 포함한 수집품을 위한 온라인 경매 플랫폼을 곧 출시할 것이라고 주장하여 투자자들을 속였다.
다음 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EA%B8%88%EC%9A%94%EC%9D%BC-%EC%83%81%EC%9C%84-5%EA%B0%9C-%ED%8A%B8%EB%A0%8C%EB%93%9C-%EC%A3%BC%EC%8B%9D-%EC%82%AC%EC%9A%B4%EB%93%9C%ED%95%98%EC%9A%B4%EB%93%9C-ai-%EA%B2%8C%EC%9E%84%EC%8A%A4/" target="_blank" rel="noopener">금요일의 인기 주식 5선: 사운드하운드 AI, 게임스탑, 룰루레몬은 무슨 일이 있었나요</a><a href="https://www.benzinga.com/24/12/42365711/fridays-top-5-trending-stocks-whats-going-on-with">?</a>
콘틸라이는 콜렉터스 커피 투자자로부터 약 2,300만 달러를 성공적으로 모금한 후, 약 610만 달러를 개인적인 용도로 횡령했다. 이 금액은 고급 상품, 아파트 및 차량 구매에 사용되었다.
미국 증권거래위원회(SEC)는 2017년경부터 콘틸라이를 조사하기 시작했으며, 이 과정에서 그는 서류를 위조하고 증언에서 거짓말을 하여 사법을 방해했다. 네바다와 콜로라도에서 기소에 직면한 콘틸라이는 러시아로 도주했다. 그는 2023년에 인터폴 적색 수배로 독일에서 체포되었고, 5월에 미국으로 송환되어 기소에 직면했다.
콘틸라이는 11월 21일에 전신 사기 혐의에 대해 유죄를 인정했다. 사건의 혐의에서 정부는 콜로라도 사건을 기각하기로 했다.
<h2 class="wp-block-heading">SEC, Kiromic BioPharma 및 CEO, CFO를 주요 정보 미공개로 기소</h2>
SEC는 화요일 키로믹 바이오파마(OTC:<a class="ticker" href="https://www.benzinga.com/stock/KRBP#OTC">KRBP</a>) 전 CEO 마우리치오 치리바-인터나티(Maurizio Chiriva-Internati)와 전 CFO 토니 톤타트(Tony Tontat)에 대해 2021년 7월 4,000만 달러를 모금한 후속 공모 전, 중, 후에 키로믹의 두 개의 암 치료제 후보에 대한 주요 정보를 공개하지 않은 혐의로 <a href="https://www.sec.gov/newsroom/press-releases/2024-189">합의된 기소</a>를 제기했다.
SEC의 명령에 따르면, 공모 2주 전에 식품의약국(FDA)가 키로믹 바이오파마에 두 약물 후보를 임상 보류에 올렸다고 통보했다.
키로믹 바이오파마는 SEC 제출 서류, 투자자 로드쇼 통화 또는 공모 이전의 실사 통화에서 FDA 임상 보류를 공개하지 않았다. 반면, 키로믹은 임상 보류의 가상적 위험과 키로믹의 사업에 미치는 잠재적 부정적 결과를 공개했다.
키로믹 바이오파마와 톤타트는 <a href="https://www.benzinga.com/pressreleases/24/12/b42295258/kiromic-biopharma-announces-settlement-of-previously-disclosed-sec-investigation">SEC의 기소를 별도의 행정 절차에서 합의</a>했으며, 치리바는 연방 지방 법원에서 기소를 합의했다. 키로믹은 자발적인 자진 신고, 협력 및 시정 조치에 비추어 민사 벌금을 부과받지 않았으며, 치리바와 톤타트은 각각 125,000달러와 20,000달러의 민사 벌금을 납부하기로 합의했다.
&#8220;이러한 해결책은 키로믹의 당시 두 고위 임원을 키로믹의 정보 공개 실패에 대해 책임을 지게 하는 동시에 키로믹의 자발적 자진 신고, 시정 조치, 사전 조치 및 직원에 대한 의미 있는 협력을 인정하는 적절한 균형을 이룬다&#8221;고 에릭 베르너(Eric Werner), SEC 포트워스 지역 사무소 이사가 말했다.

다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%9C%A0%EB%82%98%EC%9D%B4%ED%8B%B0%EB%93%9C%ED%97%AC%EC%8A%A4-%EB%B8%8C%EB%9D%BC%EC%9D%B4%EC%96%B8-%ED%86%B0%EC%8A%A8-%EC%82%AC%EB%A7%9D%EC%97%90-%EA%B9%8A%EC%9D%80-%EC%95%A0%EB%8F%84/" target="_blank" rel="noopener">유나이티드헬스케어 CEO 브라이언 톰슨, 뉴욕 호텔 밖에서 총격으로 사망</a></li>
</ul>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Kiromic BioPharma Inc Ordinary Shares

뉴스

에 대한 최신 뉴스 Kiromic BioPharma Inc Ordinary Shares (OTC:KRBP) 주식

일요일, 12월 08, 2024

뉴스

파트너 / 기고자

벤징가 글로벌